Trials / Recruiting
RecruitingNCT05704621
Secondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor Maintenance
A Randomized Phase II Study of Secondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor Maintenance
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 124 (estimated)
- Sponsor
- Korea University Guro Hospital · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized phase II study of secondary cytoreductive surgery (CRS) in patients with relapsed ovarian cancer who have progressed on PARP inhibitor maintenance.
Detailed description
The primary objective is to find out whether the CRS is beneficial in patients who have progressed on PARPi maintenance.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | secondary cytoreductive surgery | Maximum effort cytoreductive surgery |
| DRUG | chemotherapy | six cycles of platinum-based chemotherapy +/- bevacizumab |
Timeline
- Start date
- 2023-12-01
- Primary completion
- 2026-12-28
- Completion
- 2028-12-28
- First posted
- 2023-01-30
- Last updated
- 2025-03-06
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05704621. Inclusion in this directory is not an endorsement.